0000000000374305

AUTHOR

Mariagrazia Del Buono

showing 3 related works from this author

Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study

2016

Objective The biological heterogeneity of hepatocellular carcinoma (HCC) makes prognosis difficult. We translate the results of a genome-wide high-throughput analysis into a tool that accurately predicts at presentation tumour growth and survival of patients with HCC.Design Ultrasound surveillance identified HCC in 78 (training set) and 54 (validation set) consecutive patients with cirrhosis. Patients underwent two CT scans 6 weeks apart (no treatment in-between) to determine tumour volumes (V-0 and V-1) and calculate HCC doubling time. Baseline-paired HCC and surrounding tissue biopsies for microarray study (Agilent Whole Human Genome Oligo Microarrays) were also obtained. Predictors of su…

AdultMale0301 basic medicinemedicine.medical_specialtyTime FactorsCarcinoma HepatocellularTime FactorMicroarrayHepatocellular carcinomamolecular carcinogenesisGastroenterologyliver imagingHEPATOCELLULAR CARCINOMA; LIVER IMAGING; MOLECULAR CARCINOGENESIS; MOLECULAR ONCOLOGY; Adult; Aged; Aged 80 and over; Carcinoma Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neovascularization Pathologic; Prospective Studies; Survival Rate; Time Factors; Tumor Burden; Medicine (all); Gastroenterology03 medical and health sciencesmolecular oncology0302 clinical medicineHepatocellular carcinoma liver imaging molecular carcinogenesis molecular oncologyInternal medicinemedicineCarcinomaHumansDoubling timeProspective StudiesProspective cohort studySurvival rateAgedAged 80 and overNeovascularization Pathologicbusiness.industryProportional hazards modelLiver NeoplasmsGastroenterologyMiddle Agedmedicine.diseaseTumor BurdenSurvival RateProspective Studie030104 developmental biologyQuartileLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinomaDisease ProgressionFemalebusinessHumanGut
researchProduct

Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19

2021

Key Points Three-day change in angiopoietin-2 levels predicts COVID-19 in-hospital mortality, whereas the 10-day trend is associated with chronic lung disability. Angiopoietin-2 may play an important pathogenic role in patients with COVID-19, and it could be a target for new treatments.

medicine.medical_specialtyMultivariate analysis20CD34Risk Factors ...030204 cardiovascular system & hematologyGastroenterologyAntiviral AgentsAngiopoietin-203 medical and health sciences0302 clinical medicineRisk FactorsVascular BiologyInternal medicinemedicineHumans030212 general & internal medicineHospital MortalitySurvival rateProportional Hazards ModelsAntiviral AgentLungReceiver operating characteristicbusiness.industryProportional hazards modelSARS-CoV-2Interleukin-6Risk FactorHazard ratioCOVID-19HematologyBiomarker32Confidence intervalCOVID-19 Drug TreatmentHospitalizationSurvival RateAngiopoietin-2; Antiviral Agents; Area Under Curve; Biomarkers; COVID-19; Hospital Mortality; Hospitalization; Humans; Interleukin-6; Proportional Hazards Models; ROC Curve; Risk Factors; SARS-CoV-2; Survival Ratemedicine.anatomical_structureROC CurveArea Under Curvecardiovascular systemProportional Hazards ModelbusinessBiomarkersHuman
researchProduct

Enoxaparin Prevents Portal Vein Thrombosis and Liver Decompensation in Patients With Advanced Cirrhosis

2012

BACKGROUND & AIMS: We performed a randomized controlled trial to evaluate the safety and efficacy of enoxaparin, a low-molecular-weight heparin, in preventing portal vein thrombosis (PVT) in patients with advanced cirrhosis. METHODS: In a nonblinded, single-center study, 70 outpatients with cirrhosis (Child-Pugh classes B7-C10) with demonstrated patent portal veins and without hepatocellular carcinoma were assigned randomly to groups that were given enoxaparin (4000 IU/day, subcutaneously for 48 weeks; n = 34) or no treatment (controls, n = 36). Ultrasonography (every 3 months) and computed tomography (every 6 months) were performed to check the portal vein axis. The primary outcome was pre…

medicine.medical_specialtyCirrhosisIntention-to-treat analysisHepatologybusiness.industrycirrhosisGastroenterologyPortal vein trombosis; Enoxaparin; cirrhosisenoxaparin cirrhosis portal thrombosismedicine.diseasePortal vein trombosisSurgeryPortal vein thrombosislaw.inventionSpontaneous bacterial peritonitisModel for End-Stage Liver DiseaseRandomized controlled triallawHepatocellular carcinomaMedicinePortal hypertensionEnoxaparinbusinessGastroenterology
researchProduct